Ultragenyx Pharmaceutical Inc. (RARE)

Market Cap	2.91B
Revenue (ttm)	610.16M
Net Income (ttm)	-532.93M
Shares Out	96.20M
EPS (ttm)	-5.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,033,825
Open	30.05
Previous Close	30.08
Day's Range	30.05 - 30.61
52-Week Range	25.81 - 60.37
Beta	0.24
Analysts	Strong Buy
Price Target	86.64 (+185.94%)
Earnings Date	Aug 5, 2025

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 1,294
• Stock Exchange: NASDAQ
• Ticker Symbol: RARE
• Website: https://www.ultragenyx.com

Financial Performance

In 2024, Ultragenyx Pharmaceutical's revenue was $560.23 million, an increase of 29.01% compared to the previous year's $434.25 million. Losses were -$569.18 million, -6.17% less than in 2023.

Analyst Summary

According to 14 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $86.64, which is an increase of 185.94% from the latest price.

Price Target

$86.64

(185.94% upside)

Analyst Consensus: Strong Buy